PA
VXRT

Perceptive Advisors’s Vaxart VXRT Stock Holding History

Perceptive Advisors’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-23,036
Closed -$626K – 165
2014
Q3 		$626K Hold
23,036
– – 0.06% 90
2014
Q2 		$722K Sell
23,036
-14,691
-39% -$614K 0.07% 85
2014
Q1 		$2.54M Buy
+37,727
New +$2.33M 0.27% 59

Other funds holding VXRT

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors's VXRT Position: Q4 2014 in Review

Perceptive Advisors sold out of Vaxart (VXRT) in Q4 2014, closing a stake of 23,036 shares — an estimated $626K sold.

Perceptive Advisors first reported a position in VXRT in Q1 2014 and held it in 3 quarters. The position peaked at $2.54M in Q1 2014. 46 funds tracked by Wall St. Rank hold VXRT as of Q4 2014.

  • Perceptive Advisors reported no remaining Vaxart position as of Q4 2014 after selling out during the quarter.
  • Perceptive Advisors sold 23,036 Vaxart shares in Q4 2014, an estimated $626K.
  • Perceptive Advisors first reported a position in Vaxart in Q1 2014 and held it in 3 quarters.
  • Perceptive Advisors's Vaxart position peaked at $2.54M in Q1 2014.
  • 46 funds tracked by Wall St. Rank held Vaxart as of Q4 2014.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.